Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases

NCT01480583 is registered in ClinicalTrials.gov with Angiochem Inc as lead sponsor.

NCT NCT01480583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01480583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multi-center, Open-label Study Evaluating GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Lead sponsor
Angiochem Inc
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
October 31, 2015
Enrollment
85 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases, breast cancer